AbbVie Inc. — News

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (“KSF”) are investigating the propos

gurufocus.com - 2026-07-30 13:00:00

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Apogee Therapeutics, Inc. (NasdaqGM: APGE) to AbbVie (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Apogee will receive $135.11 in cash for each share of Apogee that they own. KSF is seeking to determine whether this consideration and the process that led to it are a.

businesswire.com - 2026-07-30 12:07:00

Allergan Aesthetics celebrates fourth annual JUVÉDERM ® Day with buy-one-get-one (BOGO) gift cards and double points for Allē Members This summer marks the 20th anniversary of the brand's first U.S. Food and Drug Administration (FDA) dermal filler approval Join Allē today to take advantage of limited time offers, while supplies last NORTH CHICAGO, Ill., July 30, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the return of JUVÉDERM® Day on Wednesday, August 19, 2026, with exclusive JUVÉDERM® offers for Allē Members.

prnewswire.com - 2026-07-30 08:00:00

Arkadios Wealth Advisors grew its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 5.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 71,885 shares of the company's stock after purchasing an additional 3,713 shares during the period. Arkadios Wealth Advisors' holdings in

defenseworld.net - 2026-07-30 03:59:43

But is that performance sustainable?

fool.com - 2026-07-29 17:00:00

AbbVie successfully transitioned away from Humira over the past three years. It still looks cheap relative to its long-term growth potential.

fool.com - 2026-07-29 12:36:18

RINVOQ ® is now approved in the European Union for the treatment of adult and adolescent patients with severe alopecia areata (AA) Approval was based on the pivotal Phase 3 UP-AA clinical program, which showed that RINVOQ achieved statistically significant scalp hair regrowth (Severity of Alopecia Tool (SALT) score ≤ 20) and improvements in eyebrows and eyelashes at week 24 1 RINVOQ is the first JAK inhibitor to achieve complete scalp hair regrowth (SALT = 0) versus placebo at week 24 NORTH CHICAGO, Ill., July 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg and 30 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with severe alopecia areata (AA).1 "The European Commission's approval of RINVOQ provides a new treatment option for the severe alopecia areata community in the EU with demonstrated scalp regrowth, including complete scalp hair regrowth for some, that can support management of the disease," said Roopal Thakkar, M.D.

prnewswire.com - 2026-07-29 03:00:00

RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) The approval is supported by data from the Phase 3 Viti-Up clinical program, which showed that RINVOQ achieved statistically significant total body (T-VASI 50) and facial repigmentation (F-VASI 75) from baseline at week 48, versus placebo 1 NORTH CHICAGO, Ill., July 29, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adult and adolescent patients 12 years and older with non-segmental vitiligo (NSV) who are candidates for systemic therapy.1 With this approval, RINVOQ is now the first and only systemic medication approved in the European Union for NSV, the most common form of vitiligo.2 "The European Commission's approval of RINVOQ as the first and only systemic treatment for non-segmental vitiligo is an advancement for patients living with this chronic autoimmune disease," said Roopal Thakkar, M.D.

prnewswire.com - 2026-07-29 03:00:00

AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.

zacks.com - 2026-07-28 14:11:08

AbbVie (NYSE:ABBV | ABBV Price Prediction) enters its July 31 Q2 earnings report with a 2.62% dividend yield, raised earnings guidance, and two blockbuster drugs growing above 20%.

247wallst.com - 2026-07-28 13:09:56

DGRO markets itself as a sleepy dividend fund, but its rulebook quietly funnels money toward mega-cap tech, and the compounding math behind that combination may rewrite which ETF actually wins over the next decade.

247wallst.com - 2026-07-28 11:55:49

After reporting an earnings beat last quarter, AbbVie could once again beat expectations in the second quarter, although management recently warned about the negative impact of one-time charges. Shares in the pharmaceutical company have rallied recently, so investors could use any negative aspect of the earnings release as an excuse to take profits.

fool.com - 2026-07-27 18:45:00

The 2026 Social Security COLA came in at just 2.8%, which is barely keeping pace with a grocery bill, let alone replacing a paycheck.

247wallst.com - 2026-07-27 11:40:30

Sarepta Therapeutics said on Monday it appointed former Tessera Therapeutics CEO Michael ​Severino its chief executive, effective July ‌28. The longtime AbbVie executive, will succeed Doug Ingram.

reuters.com - 2026-07-27 09:19:09

Gabelli Funds LLC reduced its position in AbbVie Inc. (NYSE: ABBV) by 31.5% in the undefined quarter, according to its most recent filing with the SEC. The fund owned 55,613 shares of the company's stock after selling 25,600 shares during the period. Gabelli Funds LLC's holdings in AbbVie were worth $12,095,000 as of

defenseworld.net - 2026-07-27 03:55:59

These two companies are pharmaceutical giants. Both seem somewhat overvalued at recent levels.

fool.com - 2026-07-26 05:47:00

Waiting until 70 to claim Social Security sounds simple until you calculate the eight years of income you need to survive without it. The dividend tier you choose to fill that gap could determine whether you arrive at 75 richer or quietly broke.

247wallst.com - 2026-07-25 18:46:57

AbbVie inherited its Dividend King status, but has proven to be a good dividend steward. The company's 2.7% yield is well-above the pharmaceutical average.

fool.com - 2026-07-25 10:15:00

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-07-24 11:01:12

AbbVie earns a buy rating, supported by accelerating top and bottom-line growth and a compelling valuation at 18x forward P/E. ABBV offers a 2.7% forward dividend yield, outperforming peers by 68%, and maintains a 12-year streak of dividend growth. Dividend growth remains central to ABBV's shareholder-friendly capital allocation, with a payout ratio of 59% and consensus expectations for continued increases.

seekingalpha.com - 2026-07-24 10:46:00

On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes AbbVie Inc. (NYSE:ABBV).

benzinga.com - 2026-07-24 07:53:15

COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, compared with investigator's choice of chemoimmunotherapy (CIT) of either rituximab plus gemcitabine plus oxaliplatin (R-GemOx) or bendamustine plus rituximab (BR) in adults.

businesswire.com - 2026-07-23 16:00:00

One basis point separates these two healthcare funds. Here is why the bigger decision is whether to own healthcare at all.

fool.com - 2026-07-23 15:39:08

When quality goes on sale, it's time to back up the truck.

fool.com - 2026-07-23 11:15:00

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.

fool.com - 2026-07-23 08:15:25

IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.

fool.com - 2026-07-23 07:49:09

Ascension Capital Advisors Inc. bought a new position in AbbVie Inc. (NYSE: ABBV) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 4,373 shares of the company's stock, valued at approximately $951,000. AbbVie comprises about 0.3% of Ascension Capital Advisors Inc.'s

defenseworld.net - 2026-07-23 04:21:32

AR Asset Management Inc. raised its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 5.3% during the first quarter, according to its most recent filing with the SEC. The firm owned 45,226 shares of the company's stock after purchasing an additional 2,266 shares during the period. AbbVie accounts for about 1.9% of

defenseworld.net - 2026-07-23 03:47:19

ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.

zacks.com - 2026-07-22 13:40:30

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.

fool.com - 2026-07-22 06:45:33

ABN Amro Investment Solutions boosted its stake in AbbVie Inc. (NYSE: ABBV) by 80.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 237,318 shares of the company's stock after buying an additional 105,906 shares during the period. ABN Amro Investment Solutions'

defenseworld.net - 2026-07-22 03:53:18

AbbVie (ABBV) closed at $256.18 in the latest trading session, marking a +1.11% move from the prior day.

zacks.com - 2026-07-21 18:47:16

It looks like a great buy-and-hold option.

fool.com - 2026-07-21 18:30:00

IXJ offers a higher dividend yield and lower volatility with global exposure, while RSPH's equal-weight approach posted a stronger 1-year return.

fool.com - 2026-07-21 13:32:42

FBT delivered 52.4% returns over one year but with deeper drawdowns, while XLV's diversified approach offers lower costs and steadier performance.

fool.com - 2026-07-21 07:57:01

Baader Bank Aktiengesellschaft grew its holdings in AbbVie Inc. (NYSE: ABBV) by 560.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,380 shares of the company's stock after buying an additional 6,263 shares during the period. Baader

defenseworld.net - 2026-07-21 05:06:56

Andra AP fonden lifted its holdings in AbbVie Inc. (NYSE: ABBV) by 44.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 283,811 shares of the company's stock after purchasing an additional 86,969 shares during the quarter.

defenseworld.net - 2026-07-21 03:17:19

PPH's concentrated 26-stock portfolio delivered 28% returns over one year, while its 2% dividend yield beats IXJ by 50 basis points.

fool.com - 2026-07-20 10:44:01

IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.

fool.com - 2026-07-20 10:17:01

Dimensional Fund Advisors LP lowered its stake in AbbVie Inc. (NYSE: ABBV) by 10.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,411,238 shares of the company's stock after selling 868,264 shares during the period. AbbVie accounts for about 0.3% of Dimensional

defenseworld.net - 2026-07-20 04:12:05

AbbVie will fund this acquisition with debt, leaving its cash reserves intact. The company should maintain its dividend program as it did after previous massive acquisitions.

fool.com - 2026-07-19 20:45:00

The three biggest US pharma names by market cap trade at very different setups right now: Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) at $247.02 screens as the most compelling on fundamentals, Eli Lilly (NYSE:LLY) at $1,156.63 looks fully valued, and AbbVie (NYSE:ABBV) at $244.11 appears stretched relative to its growth outlook.

247wallst.com - 2026-07-19 09:30:58

AIA Group Ltd raised its position in shares of AbbVie Inc. (NYSE: ABBV) by 23.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 74,580 shares of the company's stock after buying an additional 14,163 shares during the period.

defenseworld.net - 2026-07-19 04:03:30

Allspring Global Investments Holdings LLC boosted its position in shares of AbbVie Inc. (NYSE: ABBV) by 0.5% during the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 441,647 shares of the company's stock after purchasing an additional 2,169 shares during the period. Allspring

defenseworld.net - 2026-07-18 03:08:06

Boey® is the first and only rapid-onset and short-duration botulinum neurotoxin serotype E approved in Europe that adult patients can try for the temporary improvement of glabellar lines¹ Results may be seen as early as eight hours after treatment and typically wear off within approximately two to three weeks Boey® offers a differentiated treatment option for many people who are curious about facial injectables² NORTH CHICAGO, Ill., July 17, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced the European Commission has approved Boey® (trenibotulinumtoxinE) in Europe, for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines) in adult patients, when these have an important psychological impact.1 Following completion of the centralized procedure, the European Commission decision applies across all 30 European Economic Area (EEA) countries.

prnewswire.com - 2026-07-17 08:00:00

ABBV's neuroscience business is expected to post solid Q2 growth, with key brands and Vyalev in focus ahead of earnings on July 31.

zacks.com - 2026-07-16 14:26:09

AbbVie ABBV stock has risen 8.9% so far this year as investor confidence strengthened in the company's post-Humira growth strategy. Despite Humira's U.S. patent expiry in 2023, AbbVie has successfully replaced much of the blockbuster's lost revenues with strong growth from Skyrizi and Rinvoq, easing concerns over its long-term earnings outlook.

zacks.com - 2026-07-15 11:46:14

AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-07-15 10:05:27

Both AbbVie (NYSE:ABBV | ABBV Price Prediction) and Baxter International (NYSE:BAX) flashed the same technical signal this month: a golden cross, where the 50-day moving average pushed above the 200-day.

247wallst.com - 2026-07-15 07:45:54

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

zacks.com - 2026-07-14 10:30:22